Managing Cyclic Vomiting and Cannabis Hyperemesis Attacks: What the Evidence Says About Home and ER Treatment

A 2025 narrative clinical review in Neurogastroenterology & Motility maps current abortive therapies for two debilitating episodic vomiting disorders, highlighting the critical importance of early intervention during the prodromal window and underscoring how most treatment recommendations still rest on expert opinion rather than rigorous randomized trial evidence.

Why This Matters

Cyclic vomiting syndrome and cannabinoid hyperemesis syndrome cause recurring, incapacitating episodes of nausea and vomiting that drive repeated emergency department visits, significant disability, and substantial healthcare costs. Both conditions remain underdiagnosed and undertreated, in part because no universally accepted abortive protocol exists. As recognition of these disorders grows, clinicians need consolidated, practical guidance on what to do when an episode begins. A current review that synthesizes the available pharmacologic and nonpharmacologic strategies fills a genuine clinical gap, even as it exposes how thin the evidence base remains.

Clinical Summary

Cyclic vomiting syndrome (CVS) and cannabinoid hyperemesis syndrome (CHS) are episodic disorders characterized by severe nausea, vomiting, and abdominal pain that can produce dangerous complications including dehydration, electrolyte derangements, and Mallory-Weiss tears. This 2025 narrative review, published in Neurogastroenterology & Motility by investigators from the University of Pittsburgh, McMaster University, and the Cyclic Vomiting Syndrome Association, consolidates current evidence and expert opinion on abortive therapy for both conditions. The mechanistic rationale for early intervention centers on the observation that most CVS patients experience a recognizable prodrome, with symptom onset occurring a median of approximately 50 minutes before the full emetic phase begins. Acting within this narrow window with multi-agent pharmacotherapy offers the best chance of aborting an episode entirely.

The review recommends several drug classes used in combination: triptans, antiemetics such as ondansetron and promethazine, anxiolytics including alprazolam and lorazepam, NK-1 receptor antagonists like aprepitant, antipsychotics such as haloperidol and droperidol, and NSAIDs. Nonpharmacologic adjuncts including sensory reduction, hot water bathing, and topical capsaicin are discussed, with capsaicin having the most CHS-specific supporting evidence, though that evidence remains limited. The authors note that an effective abortive regimen, defined as one that aborts at least 75% of episodes, itself reduces anticipatory anxiety and neurohormonal stress responses. Critically, the review acknowledges that nearly all of these recommendations derive from case series, retrospective data, and expert consensus rather than randomized controlled trials. The authors call for rigorous comparative research and emphasize that it remains unclear whether CVS and CHS require fundamentally different abortive strategies.

Dr. Caplan’s Take

This review does something genuinely useful: it puts the available toolkit in one place for clinicians who may see these patients only a few times a year but need to act quickly when they do. The emphasis on prodromal recognition is exactly right. The gap, though, is that virtually none of these recommendations have survived the test of a well-designed randomized trial. When patients or their families ask me whether there is a proven treatment for their episodes, honesty requires acknowledging that “proven” is still aspirational for most of what we recommend. The review is a consensus map, not an evidence verdict.

In practice, I work with patients to identify their individual prodromal signals, then build a layered rescue plan they can initiate at home before things escalate. That usually means a triptan, an antiemetic, and an anxiolytic ready to go, with clear criteria for when to escalate to the emergency department. For patients with frequent ED visits, I help develop a written care plan they can present on arrival. I also address cannabis use directly and nonjudgmentally, because distinguishing CVS from CHS has real therapeutic implications. This is individualized medicine by necessity, not by choice, and we badly need the trials to catch up.

Clinical Perspective

This review sits early in the research arc for abortive therapy in CVS and CHS. It consolidates what is known but does not materially advance the evidence base, because it is a narrative synthesis rather than a systematic review or original investigation. Clinicians should treat its recommendations as structured expert opinion. The emphasis on prodromal-phase intervention is clinically intuitive and supported by limited observational data, but the specific drug combinations and sequences have not been compared head-to-head in controlled settings. The review does not provide a formal grading of evidence strength, which makes it difficult to distinguish well-supported recommendations from those resting on minimal data. For patient-facing conversations, it is reasonable to describe these strategies as “current best practice based on clinical experience” rather than as established, evidence-based protocols.

Several pharmacologic considerations deserve attention. Triptans carry cardiovascular contraindications that must be screened for. Benzodiazepines introduce dependence risk in a population that may experience frequent episodes. Droperidol and haloperidol require QTc monitoring. NK-1 antagonists such as aprepitant can interact with CYP3A4 substrates, potentially affecting concurrent medications. For patients using cannabis, clinicians should assess use patterns carefully, as ongoing cannabis exposure may perpetuate CHS episodes regardless of pharmacotherapy. The single most actionable step a clinician can take today is to help each patient develop a written, individualized abortive plan that specifies prodromal recognition cues, a staged medication sequence, and explicit emergency department escalation criteria.

Study at a Glance

Study Type

Narrative clinical review

Population

Adults and adolescents with cyclic vomiting syndrome or cannabinoid hyperemesis syndrome

Intervention

Pharmacologic and nonpharmacologic abortive therapies (triptans, antiemetics, anxiolytics, NK-1 antagonists, antipsychotics, NSAIDs, capsaicin, hot water bathing, sensory reduction)

Comparator

Not applicable (narrative review; no head-to-head comparisons conducted)

Primary Outcomes

Episode abortion, symptom reduction, and practical clinical guidance for home and emergency department settings

Sample Size

Not applicable (no original patient data)

Journal

Neurogastroenterology & Motility

Year

2025 (accepted August 2024)

DOI

10.1111/nmo.14901

Funding Source

Not specified; author affiliations include University of Pittsburgh, Cyclic Vomiting Syndrome Association, and McMaster University

What Kind of Evidence Is This

This is a narrative clinical review, not a systematic review or meta-analysis. It occupies the lower tiers of the evidence hierarchy, drawing on selectively cited literature and expert opinion rather than a reproducible, comprehensive search strategy. The most important inference constraint this imposes is that the recommendations cannot be assumed to reflect the totality of available evidence; the literature coverage may be incomplete or shaped by author perspective, and no formal risk-of-bias assessment of cited studies is provided.

How This Fits With the Broader Literature

This review is consistent with prior consensus guidelines, including the 2019 Rome Foundation working team report on CVS and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) consensus statements, which similarly emphasize early abortive intervention and multi-agent pharmacotherapy. It extends those documents by giving more detailed attention to CHS-specific adjuncts such as topical capsaicin and hot water bathing, and by explicitly addressing emergency department care planning. However, the evidence landscape has not materially changed: no large randomized controlled trial of abortive therapy for either CVS or CHS has been published. The review confirms established clinical reasoning rather than challenging it, and the absence of new primary data means it functions primarily as a practical consolidation rather than a paradigm shift.

Common Misreadings

The most likely overinterpretation is treating the multi-agent protocols described here as evidence-based standard of care. The review presents them as reasonable clinical practice, but they have not been validated by randomized controlled trials. Citing this paper as proof that a specific drug combination “works” for CVS or CHS would exceed what the evidence supports. Similarly, the 75% episode-abortion threshold mentioned as a benchmark for an effective regimen is a clinical target proposed by the authors, not a number derived from controlled outcome data. Clinicians should understand these recommendations as expert-informed starting points for individualization, not as settled treatment algorithms.

Bottom Line

This narrative review provides a useful, consolidated reference for managing acute CVS and CHS episodes at home and in the emergency department. It reinforces that early prodromal intervention with multi-agent pharmacotherapy represents current best practice. It does not, however, establish that any specific protocol is superior to another, and it does not generate new evidence. Clinical decisions should reflect individualized judgment, and the field urgently needs randomized controlled trials to move these recommendations from expert opinion toward evidence-based certainty.

References

1. Narrative clinical review on abortive therapy for cyclic vomiting syndrome and cannabinoid hyperemesis syndrome. Neurogastroenterology & Motility. 2025. DOI: 10.1111/nmo.14901.